Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Cited by (1,012)

Items 101–200 of 1,012

1. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
   Lauren A. Byers, Jing Wang, Monique B. Nilsson, Junya Fujimoto, Pierre Saintigny, John S. Yordy, Uma P. Giri, Michael Peyton, You Hong Fan, Lixia Diao et al. · 2012 · Cancer Discovery
2. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
   Li, Qing, Geng, Shan, Luo, Hao, Wang, Wei, Mo, Ya-Qi, Luo, Qing, Wang, Lu, Song, Guan-Bin, Sheng, Jian-Peng, Xu, Bo · 2024 · Signal Transduction and Targeted Therapy
3. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
   Amit M. Oza, David Cibula, Ana Oaknin Benzaquen, Christopher John Poole, Ron H.J. Mathijssen, Gabe S. Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger W. Hirte et al. · 2014 · The Lancet Oncology
4. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
   Apostolia Maria Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald Steven Falchook, Siqing Fu, Sarina Anne Piha-Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra et al. · 2012 · Clinical Cancer Research
5. Genetics of breast cancer: a topic in evolution
   Stacey Shiovitz, Larissa A. Korde · 2015 · Annals of Oncology
6. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
   Kathleen N. Moore, Angeles Alvarez Secord, Melissa Ann Geller, David Scott Miller, Noelle Gillette Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M. Oza et al. · 2019 · The Lancet Oncology
7. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
   Polak, Paz, Kim, Jaegil, Braunstein, Lior Z, Karlic, Rosa, Haradhavala, Nicholas J, Tiao, Grace, Rosebrock, Daniel, Livitz, Dimitri, Kübler, Kirsten, Mouw, Kent W et al. · 2017 · Nature Genetics
8. Germline mutations in RAD51D confer susceptibility to ovarian cancer
   Chey Loveday, Clare Turnbull, Emma Ramsay, Deborah Hughes, Elise Ruark, Jessica R. Frankum, Georgina R. Bowden, Bolot Kalmyrzaev, Margaret Warren-Perry, Katie M.G. Snape et al. · 2011 · Nature Genetics
9. High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
   Nikhil Wagle, Michael F. Berger, Matthew J. Davis, Brendan S. Blumenstiel, Matthew T. DeFelice, Panisa Pochanard, Matthew D. Ducar, Paul Van Hummelen, Laura E. MacConaill, William C. Hahn et al. · 2011 · Cancer Discovery
10. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination
    Tang, Jiangbo, Cho, Nam Woo, Cui, Gaofeng, Manion, Erica M, Shanbhag, Niraj M, Botuyan, Maria Victoria, Mer, Georges, Greenberg, Roger A · 2013 · Nature Structural & Molecular Biology
11. Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
    Janneke E. Jaspers, Ariena J. Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A.L. Zander, Rinske Drost, Ellen Wientjens, Jiuping Jay Ji, Amal Aly et al. · 2012 · Cancer Discovery
12. Breast Cancer Treatments: Updates and New Challenges
    Anna Burguin, Caroline Diorio, Francine Durocher · 2021 · Journal of Personalized Medicine
13. <i>ATM</i> Mutations in Patients with Hereditary Pancreatic Cancer
    Roberts, Nicholas J., Jiao, Yuchen, Yu, Jun, Kopelovich, Levy, Petersen, Gloria M., Bondy, Melissa L., Gallinger, Steven, Schwartz, Ann G., Syngal, Sapna, Cote, Michele L. et al. · 2012 · Cancer Discovery
14. Cellular Heterogeneity and Molecular Evolution in Cancer
    Vanessa Almendro, Andriy Marusyk, Kornélia Polyák · 2012 · Annual Review of Pathology Mechanisms of Disease
15. Latest research and treatment of advanced-stage epithelial ovarian cancer
    Robert Louis Coleman, Bradley J. Monk, Anil K. Sood, Thomas J. Herzog · 2013 · Nature Reviews Clinical Oncology
16. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
    Manfred Kaufmann, Gϋnter von Minckwitz, E Mamounas, David Cameron, LA Carey, Massimo Cristofanilli, Carsten Denkert, Wolfgang EIERMANN, Michael Gnant, Jay R. Harris et al. · 2011 · Annals of Surgical Oncology
17. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
    Sausen, Mark, Phallen, Jillian, Adleff, Vilmos, Jones, Siân, Leary, Rebecca J., Barrett, Michael T., Anagnostou, Valsamo, Parpart-Li, Sonya, Murphy, Derek, Kay Li, Qing et al. · 2015 · Nature Communications
18. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
    Kim, Seung Min, Yang, Yoosoo, Oh, Seung Ja, Hong, Yeonsun, Seo, Minkoo, Jang, Mihue · 2017 · Journal of Controlled Release
19. Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
    Panagiotis A. Konstantinopoulos, Dimitrios Spentzos, Beth Y. Karlan, Toshiyasu Taniguchi, Elena Fountzilas, Nancy J. Francoeur, Douglas A. Levine, Stephen A. Cannistra · 2010 · Journal of Clinical Oncology
20. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
    Yuqiao Shen, Farah L. Rehman, Ying Feng, Julia Boshuizen, Ilirjana Bajrami, Richard J. R. Elliott, Bing Wang, Christopher J. Lord, Leonard E. Post, Alan Ashworth · 2013 · Clinical Cancer Research
21. Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
    Christopher J. Lord, Andrew N.J. Tutt, Alan Ashworth · 2014 · Annual Review of Medicine
22. Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
    Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y. Karlan, Amnon Amit, Katherine M. Bell‐McGuinn, Lee-may Chen, Michael Leonard Friedlander et al. · 2011 · Journal of Clinical Oncology
23. Synthetic lethality as an engine for cancer drug target discovery
    Alan Huang, Levi A. Garraway, Alan Ashworth, Barbara L. Weber · 2019 · Nature Reviews Drug Discovery
24. Luminal breast cancer: from biology to treatment
    Michail Ignatiadis, Christos P. Sotiriou · 2013 · Nature Reviews Clinical Oncology
25. Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
    Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas Andreas Lyssiotis et al. · 2012 · Cancer Discovery
26. Dissecting the Heterogeneity of Triple-Negative Breast Cancer
    Otto Metzger, Andrew N.J. Tutt, Evandro de Azambuja, Kamal S. Saini, Giuseppe Viale, Sherene Loi, Ian Bradbury, Judith M. Bliss, Hatem A. Azim, PA Ellis et al. · 2012 · Journal of Clinical Oncology
27. Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research
    Ivashkevich, Alesia, Redon, Christophe E., Nakamura, Asako J., Martin, Roger F., Martin, Olga A. · 2012 · Cancer Letters
28. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
    Elisabet Wahlberg, T. Karlberg, Ekaterina Kouznetsova, Natalia Markova, Antonio Macchiarulo, A.G. Thorsell, Ewa Pol, Åsa Frostell, Torun Ekblad, Delal Öncü et al. · 2012 · Nature Biotechnology
29. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
    Sylvie M. Noordermeer, Haico van Attikum · 2019 · Trends in Cell Biology
30. Mechanisms of resistance to therapies targeting BRCA-mutant cancers
    Christopher J. Lord, Alan Ashworth · 2013 · Nature Medicine
31. Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
    Himisha Beltran, Roman Yelensky, Garrett Michael Frampton, Kyung Park, Sean R. Downing, Theresa Y. MacDonald, Mirna V. Jarosz, Doron Lipson, Scott T. Tagawa, David M. Nanus et al. · 2012 · European Urology
32. Dual Roles of PARP-1 Promote Cancer Growth and Progression
    Matthew Joseph Schiewer, Jonathan F. Goodwin, Sumin Han, John Chad Brenner, Michael A. Augello, Jeffry L. Dean, Fengzhi Liu, Jamie L. Planck, Preethi Ravindranathan, Arul M. Chinnaiyan et al. · 2012 · Cancer Discovery
33. The genesis and evolution of high-grade serous ovarian cancer
    David D.L. Bowtell · 2010 · Nature reviews. Cancer
34. miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
    Patryk Moskwa, Francesca Meteora Buffa, Yunfeng Pan, Rohit A. Panchakshari, Ponnari Gottipati, Ruth J. Muschel, John S. Beech, Ritu Kulshrestha, Kotb Abdelmohsen, David M. Weinstock et al. · 2010 · Molecular Cell
35. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
    Shiyu Zhang, Robert Royer, Song Li, John R McLaughlin, Barry P. Rosen, Harvey A. Risch, Isabel Fan, Linda Bradley, Patricia Ann Shaw, Steven Alexander Narod · 2011 · Gynecologic Oncology
36. Genetic Interactions in Cancer Progression and Treatment
    Alan Ashworth, Christopher J. Lord, Jorge Sergio Reis-Filho · 2011 · Cell
37. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
    JANE C. GOODALL, Joaquı́n Mateo, Wei Yuan, Helen Mossop, Núria Porta, Susana Miranda, Raquel Pérez-López, David I. Dolling, Dan R. Robinson, Shahneen Kaur Sandhu et al. · 2017 · Cancer Discovery
38. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
    Marco Gerlinger, Charles Swanton · 2010 · British Journal of Cancer
39. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
    Alan Ashworth, Christopher J. Lord · 2018 · Nature Reviews Clinical Oncology
40. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
    Schnitt, Stuart J · 2010 · Modern Pathology
41. Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
    Kirsten M. Timms, Victor Abkevich, Elisha Hughes, Chris D. Neff, Julia Reid, Brian Morris, Saritha Kalva, Jennifer Potter, Thanh V Tran, Jian Chen et al. · 2014 · Breast Cancer Research
42. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis
    Stanley Lipkowitz, Allan M. Weissman · 2011 · Nature reviews. Cancer
43. Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
    John Chad Brenner, Bushra Ateeq, Yong Li, Anastasia K. Yocum, Qi Cao, Irfan Ahmed Asangani, Sonam Patel, Xiaoju Wang, Hallie Liang, Jindan Yu et al. · 2011 · Cancer Cell
44. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
    The UKGPCS Collaborators, Zsofia Kote‐Jarai, Daniel A. Leongamornlert, Edward J. Saunders, Malgorzata Tymrakiewicz, Elena Castro, Nadiya Mahmud, Michelle Guy, Sandra E. Edwards, L O'Brien et al. · 2011 · British Journal of Cancer
45. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
    Pietanza, M. Catherine, Waqar, Saiama N., Krug, Lee M., Dowlati, Afshin, Hann, Christine L., Chiappori, Alberto, Owonikoko, Taofeek K., Woo, Kaitlin M., Cardnell, Robert J., Fujimoto, Junya et al. · 2018 · Journal of Clinical Oncology
46. Human cancers express mutator phenotypes: origin, consequences and targeting
    Lawrence A. Loeb · 2011 · Nature reviews. Cancer
47. Triple-negative breast cancer: is there a treatment on the horizon?
    Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J. Rosol, Xiyun Deng · 2016 · Oncotarget
48. Triple-negative breast cancer: treatment challenges and solutions
    Guy Jérusalem, Joëlle Collignon, Hélène Schroeder, Laurence Lousberg · 2016 · Breast Cancer Targets and Therapy
49. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
    Stephanie A. Yazinski, Valentine Comaills, Rémi Buisson, Marie‐Michelle Genois, Hai Dang Nguyen, Chu Kwen Ho, Tanya Todorova Kwan, Robert Tyler Morris, Sam Lauffer, André Nussenzweig et al. · 2017 · Genes & Development
50. Fanconi anaemia and cancer: an intricate relationship
    Grzegorz Nalepa, D. Wade Clapp · 2018 · Nature reviews. Cancer
51. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
    Johann Sebastian De Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi K Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John Victor Heymach, David Carl Smith et al. · 2017 · Cancer Discovery
52. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
    Murga, Matilde, Campaner, Stefano, Lopez-Contreras, Andres J, Toledo, Luis I, Soria, Rebeca, Montaña, Maria F, D'Artista, Luana, Schleker, Thomas, Guerra, Carmen, Garcia, Elena et al. · 2011 · Nature Structural &amp; Molecular Biology
53. Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
    Alan D. D’Andrea · 2010 · New England Journal of Medicine
54. The fate of chemoresistance in triple negative breast cancer (TNBC)
    Elma Anna O'Reilly, Luke Gubbins, Shiva Sharma, Riona Tully, Matthew Ho, Karolina Weiner‐Gorzel, John McCaffrey, Michèle Harrison, Fiona M. Furlong, Malcolm Kell et al. · 2015 · BBA Clinical
55. DNA Damage/Repair Management in Cancers
    Jehad F. Alhmoud, John F. Woolley, Ala‐Eddin Al Moustafa, Mohammed Imad Malki · 2020 · Cancers
56. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
    Dai Horiuchi, Leonard Kusdra, Noelle E. Huskey, Sanjay J. Chandriani, Marc E. Lenburg, Ana Maria Gonzalez-Angulo, Katelyn J. Creasman, Alexey V. Bazarov, James W. Smyth, Sarah Davis et al. · 2012 · The Journal of Experimental Medicine
57. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
    Ewa Gogola, Alexandra A. Duarte, Julian R. de Ruiter, Wouter W. Wiegant, Jonas Andreas Schmid, Roebi de Bruijn, Dominic I. James, Sergi Guerrero Llobet, Daniël J. Vis, Stefano Annunziato et al. · 2018 · Cancer Cell
58. Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
    Dana V. Ferraris · 2010 · Journal of Medicinal Chemistry
59. An update on PARP inhibitors—moving to the adjuvant setting
    Amir Sonnenblick, Evandro de Azambuja, Hatem A. Azim, Martine J Piccart · 2014 · Nature Reviews Clinical Oncology
60. Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
    Bryan T. Hennessy, Kirsten M. Timms, Mark Stafford Carey, Alexander Gutin, Larissa Alejandra Meyer, Darl D. Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn et al. · 2010 · Journal of Clinical Oncology
61. Proteome-wide Identification of Poly(ADP-Ribosyl)ation Targets in Different Genotoxic Stress Responses
    Stephanie Jungmichel, Florian Rosenthal, Matthias Altmeyer, Jiri Lukas, Michael O. Hottiger, Michael Lund Nielsen · 2013 · Molecular Cell
62. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
    Elena Castro, Chee Leng Goh, Daniel A. Leongamornlert, Edward J. Saunders, Malgorzata Tymrakiewicz, Tokhir Dadaev, Koveela Govindasami, Michelle Guy, Steve Ellis, Debra Frost et al. · 2014 · European Urology
63. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
    Curtin, Nicola J., Szabo, Csaba · 2013 · Molecular Aspects of Medicine
64. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
    A.G. Thorsell, Torun Ekblad, T. Karlberg, Mirjam Löw, A.F. Pinto, L. Tresaugues, Martin Moche, Michael S. Cohen, Herwig Schuler · 2016 · Journal of Medicinal Chemistry
65. Cancer chemoprevention: a rapidly evolving field
    William P. Steward, Karen Brown · 2013 · British Journal of Cancer
66. Personalised cancer medicine
    Sarah E. Jackson, John David Chester · 2014 · International Journal of Cancer
67. Targeting Breast Cancer Stem Cells
    Suling Liu, Max S. Wicha · 2010 · Journal of Clinical Oncology
68. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition
    Przemek M. Krawczyk, Berina Eppink, Jeroen Essers, Jan Stap, Hans M. Rodermond, Hanny Odijk, Alex N. Zelensky, Chris van BREE, Lukas J.A. Stalpers, Marrije R. Buist et al. · 2011 · Proceedings of the National Academy of Sciences
69. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
    Quereda, Victor, Bayle, Simon, Vena, Francesca, Frydman, Sylvia M., Monastyrskyi, Andrii, Roush, William R., Duckett, Derek R. · 2019 · Cancer Cell
70. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
    J.-M. Lee, Jonathan Andrew Ledermann, Elise C. Kohn · 2013 · Annals of Oncology
71. DNA-Damage Response in Tissue-Specific and Cancer Stem Cells
    Cédric Blanpain, Mary Mohrin, Panagiota A. Sotiropoulou, Emmanuelle A. Passegue · 2011 · Cell stem cell
72. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
    Benjamin H. Lok, Eric E. Gardner, Valentina E. Schneeberger, Ai Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A. Teicher, Nadeem Riaz, Simon N. Powell et al. · 2016 · Clinical Cancer Research
73. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer
    Christopher P. Childers, Kimberly K. Childers, Melinda A Maggard-Gibbons, James A. Macinko · 2017 · Journal of Clinical Oncology
74. Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
    Songmin Ying, Freddie Charles Hamdy, Thomas Helleday · 2012 · Cancer Research
75. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition
    Lynnette Robyn Ferguson, Helen Chen, Andrew Richard Collins, Marisa Connell, Giovanna L.M. Damia, Santanu Dasgupta, Meenakshi Malhotra, Alan Keith Meeker, Amedeo Amedei, Amr Amin et al. · 2015 · Seminars in Cancer Biology
76. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24
    Ellen L. Goode, The Australian Cancer Study (Ovarian Cancer), The Australian Ovarian Cancer Study Group, Georgia Chenevix‐Trench, Honglin Song, Susan J. Ramus, Maria Notaridou, Kate Lawrenson, Martin Widschwendter, Robert Alan Vierkant et al. · 2010 · Nature Genetics
77. STING pathway agonism as a cancer therapeutic
    Blake A. Flood, Emily F. Higgs, Shuyin Li, Jason J. Luke, Thomas Frank Gajewski · 2019 · Immunological Reviews
78. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
    Louise J. Barber, Shahneen Kaur Sandhu, Lina Chen, James Campbell, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Daniel Nava Rodrigues, Jorge Sergio Reis-Filho, Víctor Moreno et al. · 2012 · The Journal of Pathology
79. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
    Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada, Paul W.G. Wijnhoven, Valeria Follia, Neil H. James, Paul M. Farrington, Ankur Karmokar, Sophie E. Willis, Jonathan Cairns et al. · 2019 · Nature Communications
80. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
    Javier Mauricio Medina Salcedo, Goldie Oza, Ashutosh Kumar Sharma, L. Arriaga, José Manuel Hernández Hernández, Vincent M. Rotello, José Tapia-Ramı́rez · 2020 · International Journal of Environmental Research and Public Health
81. Making sense of cancer genomic data
    Lynda Chin, William C. Hahn, Gad A. Getz, Matthew M. Meyerson · 2011 · Genes & Development
82. PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers
    Patrick Glen Pilie, Carl Michael Gay, Lauren A. Byers, Mark J. O’Connor, Timothy Anthony Yap · 2019 · Clinical Cancer Research
83. Translating cancer research into targeted therapeutics
    Johann Sebastian De Bono, Alan Ashworth · 2010 · Nature
84. Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection
    Andrew Becker · 2014 · World Journal of Gastroenterology
85. Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors
    Bronson D. Riley, Julie O. Culver, Cécile Skrzynia, Leigha A. Senter, June A. Peters, Josephine Wagner Costalas, Faith Callif‐Daley, Sherry Grumet, Katherine S. Hunt, Rebecca S. Nagy et al. · 2011 · Journal of Genetic Counseling
86. Biomarkers for Homologous Recombination Deficiency in Cancer
    Hoppe, Michal M, Sundar, Raghav, Tan, David S P, Jeyasekharan, Anand D · 2018 · JNCI: Journal of the National Cancer Institute
87. Subtyping of triple‐negative breast cancer: Implications for therapy
    Vandana Gupta Abramson, Brian David Lehmann, Tarah Jean Ballinger, Jennifer A. Pietenpol · 2014 · Cancer
88. Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
    Timothy Anthony Yap, Aurelius Gabriel Omlin, Johann Sebastian De Bono · 2013 · Journal of Clinical Oncology
89. Genomic Scars as Biomarkers of Homologous Recombination Deficiency and Drug Response in Breast and Ovarian Cancers
    Watkins, Johnathan A, Irshad, Sheeba, Grigoriadis, Anita, Tutt, Andrew NJ · 2014 · Breast Cancer Research
90. A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
    Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nick Orr, Marina Parton, Ian E. Smith, Jorge Sergio Reis-Filho et al. · 2010 · Clinical Cancer Research
91. Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
    PHILIP G. JONES, Sergio Altamura, Julia K. Boueres, Federica Ferrigno, Massimiliano Fonsi, Claudia Giomini, Stefania Lamartina, Edith S. Monteagudo, Jesus M. Ontoria, Maria Vittoria Orsale et al. · 2009 · Journal of Medicinal Chemistry
92. Advances in PET imaging of cancer
    Johannes Schwenck, Dominik Sonanini, Jonathan M. Cotton, Hans‐Georg Rammensee, Christian la Fougère, Lars Zender, Bernd Jürgen Pichler · 2023 · Nature reviews. Cancer
93. The role of PARP in DNA repair and its therapeutic exploitation
    Milind M. Javle, Nicola J. Curtin · 2011 · British Journal of Cancer
94. Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
    Mo Li, Xiaochun Yu · 2013 · Cancer Cell
95. Characteristics of triple-negative breast cancer
    Tim C. de Ruijter, Jürgen Veeck, Joep P.J. de Hoon, Manon van Engeland, Vivianne C. G. Tjan‐Heijnen · 2010 · Journal of Cancer Research and Clinical Oncology
96. Therapeutic strategies in epithelial ovarian cancer
    Ayako Kim, Yutaka Ueda, Tetsuji Naka, Takayuki Enomoto · 2012 · Journal of Experimental & Clinical Cancer Research
97. Synthetic lethality: General principles, utility and detection using genetic screens in human cells
    Sebastian M. B. Nijman · 2010 · FEBS Letters
98. Molecular Classification of Gastric Cancer: A New Paradigm
    Manish A. Shah, Raya Khanin, Laura H. Tang, Yelena Yuriy Janjigian, David S. Klimstra, Hans Gerdes, David Paul Kelsen · 2011 · Clinical Cancer Research
99. Targeted Therapies for Triple-Negative Breast Cancer
    Tomás G. Lyons · 2019 · Current Treatment Options in Oncology
100. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
     Rémi Buisson, Anne‐Marie Dion‐Côté, Yan Coulombe, Hélène Launay, Hong Cai, Alicja Z. Stasiak, Andrzej Stasiak, Bing Xia, Jean‐Yves Masson · 2010 · Nature Structural & Molecular Biology